Pazopanib Confers a Progression-free Survival in a Patient with Ewing's Sarcoma/Primitive Neuroectodermal Tumor of the Lung

Intern Med. 2019 May 1;58(9):1335-1339. doi: 10.2169/internalmedicine.1549-18. Epub 2019 Jan 10.

Abstract

Ewing's sarcoma (ES)/primitive neuroectodermal tumors (PNETs) are highly malignant neoplasms that usually affect the bones and soft tissues in children and young adults. ES/PNET of the lung is very rare and is associated with a poor prognosis. We herein report a case of ES/PNET of the left lung in a 45-year-old man. He was treated with neoadjuvant chemotherapy and pneumonectomy, but unfortunately his disease recurred 1.5 months after surgery. He was started on pazopanib, which resulted in a five-month progression-free survival. To our knowledge, this is the first demonstration of pazopanib efficacy in ES/PNET of the lung.

Keywords: Ewing's sarcoma; pazopanib; primitive neuroectodermal tumors.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chemotherapy, Adjuvant
  • Fatal Outcome
  • Humans
  • Indazoles
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / surgery
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Neuroectodermal Tumors, Primitive / drug therapy*
  • Pneumonectomy / methods
  • Progression-Free Survival
  • Pyrimidines / therapeutic use*
  • Sarcoma, Ewing / drug therapy*
  • Sarcoma, Ewing / surgery
  • Sulfonamides / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib